NO20020151L - Veksthormonformuleringer - Google Patents

Veksthormonformuleringer

Info

Publication number
NO20020151L
NO20020151L NO20020151A NO20020151A NO20020151L NO 20020151 L NO20020151 L NO 20020151L NO 20020151 A NO20020151 A NO 20020151A NO 20020151 A NO20020151 A NO 20020151A NO 20020151 L NO20020151 L NO 20020151L
Authority
NO
Norway
Prior art keywords
growth hormone
result
temperatures
formulation
mannitol
Prior art date
Application number
NO20020151A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020151D0 (no
Inventor
Bernhard Siebold
John Stevens
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20020151(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of NO20020151D0 publication Critical patent/NO20020151D0/no
Publication of NO20020151L publication Critical patent/NO20020151L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
NO20020151A 1999-07-12 2002-01-11 Veksthormonformuleringer NO20020151L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation
PCT/GB2000/002664 WO2001003741A1 (en) 1999-07-12 2000-07-11 Growth hormone formulations

Publications (2)

Publication Number Publication Date
NO20020151D0 NO20020151D0 (no) 2002-01-11
NO20020151L true NO20020151L (no) 2002-03-12

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020151A NO20020151L (no) 1999-07-12 2002-01-11 Veksthormonformuleringer

Country Status (25)

Country Link
US (1) US20060029635A1 (cg-RX-API-DMAC7.html)
EP (1) EP1194170B1 (cg-RX-API-DMAC7.html)
JP (3) JP2003504346A (cg-RX-API-DMAC7.html)
KR (1) KR20020031388A (cg-RX-API-DMAC7.html)
CN (1) CN1360506A (cg-RX-API-DMAC7.html)
AR (1) AR024728A1 (cg-RX-API-DMAC7.html)
AT (1) ATE386501T1 (cg-RX-API-DMAC7.html)
AU (1) AU775107C (cg-RX-API-DMAC7.html)
BR (1) BR0013162A (cg-RX-API-DMAC7.html)
CA (1) CA2378949C (cg-RX-API-DMAC7.html)
CZ (1) CZ200260A3 (cg-RX-API-DMAC7.html)
DE (1) DE60038118T2 (cg-RX-API-DMAC7.html)
ES (1) ES2300268T3 (cg-RX-API-DMAC7.html)
HK (1) HK1046358A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0202189A3 (cg-RX-API-DMAC7.html)
IL (2) IL147253A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02000404A (cg-RX-API-DMAC7.html)
NO (1) NO20020151L (cg-RX-API-DMAC7.html)
NZ (1) NZ516507A (cg-RX-API-DMAC7.html)
PL (1) PL353238A1 (cg-RX-API-DMAC7.html)
SI (1) SI1194170T1 (cg-RX-API-DMAC7.html)
SK (1) SK252002A3 (cg-RX-API-DMAC7.html)
TR (1) TR200200034T2 (cg-RX-API-DMAC7.html)
TW (1) TWI247608B (cg-RX-API-DMAC7.html)
WO (1) WO2001003741A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
EP1536835A1 (en) * 2002-07-09 2005-06-08 Sandoz AG Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
CA2516314C (en) * 2003-03-18 2012-01-03 Ares Trading Sa Liquid growth hormone formulation and process of preparation thereof
JP2007506683A (ja) * 2003-09-25 2007-03-22 カンジェーン コーポレイション ヒト成長ホルモン剤およびその調整方法と使用方法
WO2005063298A1 (en) * 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
AU2005237775B2 (en) * 2004-04-07 2010-03-04 Ares Trading S.A. Liquid growth hormone formulation
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
EP2501367B1 (en) * 2009-11-17 2015-01-21 Ipsen Pharma S.A.S. Formulation for HGH and RHIGF-1 combination
EP2736490A1 (en) 2011-07-25 2014-06-04 Sandoz AG Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
WO2017098798A1 (ja) 2015-12-10 2017-06-15 三菱瓦斯化学株式会社 光硬化性組成物及び光学材料
JP6172880B1 (ja) * 2017-02-01 2017-08-02 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
EP3811962A4 (en) * 2018-06-25 2022-03-16 JCR Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
EP4243770A1 (en) * 2020-11-16 2023-09-20 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled multi-dose injection devices without cloud point
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
EP0211601A3 (en) * 1985-07-30 1988-01-13 International Minerals And Chemical Corporation Stabilization of growth promoting hormones
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
WO1994003198A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
DK0549694T3 (da) * 1990-09-21 1995-10-16 Novo Nordisk As Adaptertop
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
ES2169351T3 (es) * 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
WO2001003741A1 (en) 2001-01-18
JP2014208656A (ja) 2014-11-06
PL353238A1 (en) 2003-11-03
EP1194170B1 (en) 2008-02-20
ATE386501T1 (de) 2008-03-15
US20060029635A1 (en) 2006-02-09
BR0013162A (pt) 2002-05-28
DE60038118T2 (de) 2009-03-05
IL147253A0 (en) 2002-08-14
JP5941496B2 (ja) 2016-06-29
CA2378949A1 (en) 2001-01-18
AU775107B2 (en) 2004-07-15
HUP0202189A2 (en) 2002-10-28
WO2001003741B1 (en) 2001-04-19
TR200200034T2 (tr) 2002-05-21
AR024728A1 (es) 2002-10-23
TWI247608B (en) 2006-01-21
HK1046358A1 (zh) 2003-01-10
CA2378949C (en) 2015-03-31
JP2003504346A (ja) 2003-02-04
IL147253A (en) 2007-07-24
SI1194170T1 (sl) 2008-10-31
CN1360506A (zh) 2002-07-24
MXPA02000404A (es) 2004-05-21
NZ516507A (en) 2004-02-27
CZ200260A3 (cs) 2002-04-17
AU5997500A (en) 2001-01-30
KR20020031388A (ko) 2002-05-01
NO20020151D0 (no) 2002-01-11
SK252002A3 (en) 2002-06-04
HUP0202189A3 (en) 2003-07-28
EP1194170A1 (en) 2002-04-10
AU775107C (en) 2005-02-24
DE60038118D1 (de) 2008-04-03
JP2012051891A (ja) 2012-03-15
ES2300268T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
NO20020151L (no) Veksthormonformuleringer
CN108107210B (zh) 一种髓过氧化物酶冻干校准品的制备方法及冻干保护液
JP2019533442A5 (cg-RX-API-DMAC7.html)
DE60221621D1 (de) Lagerstabiles Nahrungsmittelprodukt enthaltend Molkenprotein, Verfahren zu seiner Herstellung und Verwendung
CN108315261A (zh) 一种食用菌保藏培养基及其制备方法
CA2463681A1 (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
CN103656661B (zh) 猪乙型脑炎活疫苗耐热冻干保护剂、其制备方法及应用
US20030186212A1 (en) Semen extender composition and methods for manufacturing and using
BRPI0509321B1 (pt) Processos de preparação na panificação de um melhorador líquido e de uma massa para produto cozido de panificação, melhorador e uso de um melhorador
CN101019570B (zh) 哈密瓜专用保鲜剂
CN101642572A (zh) 海洋微生物溶菌酶保护冻干粉的制造方法
CN105925483A (zh) 一种真姬菇菌种低温保藏及解冻方法
WO2023072137A1 (zh) 蛋白稳定剂、试剂盒和保护蛋白的方法
US6579707B2 (en) Stabilization of enzymes during freezing
CN110065688A (zh) 一种猪粪源生物肥料的生产包装方法
CN108077244A (zh) 一种长效猪精液稀释粉
CN116549652A (zh) 一种冻干保护剂、冻干试剂及其制备方法
KR102123805B1 (ko) 클로렐라의 냉동 보관 방법
Williamson Selective media in the enumeration of bacteria in pitching yeasts
CN111742980A (zh) 一种生物膜抑制剂及其制备方法和应用
CN107174663A (zh) 疫苗冻干保护剂
US7022649B2 (en) Composition for inoculating legumes and method therefor
CN101775380B (zh) 甜菜碱作为丙氨酸氨基转移酶稳定剂的应用及丙氨酸氨基转移酶校准品组合物
CN108165495A (zh) 一种用于微生物菌种冷藏保存的稳定剂
CN108704129A (zh) 一种猪传染性胃肠炎、猪流行性腹泻二联活疫苗的制备方法

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application